SCHEMBL14724517

SCHEMBL14724517

CCOC(=O)C(C)(NC(=O)c1ccc(-c2ccccc2)cc1)C(=O)OCC

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.49
CYP1A2 P05177 1/20 0.49
MAPK1 P28482 2/20 0.47
NPC1 O15118 3/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 1/20 0.45
RECQL P46063 1/20 0.45
MMP8 P22894 1/20 0.45
CYP26A1 O43174 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14724481 0.82 MAPK1 (0.41) RAB9AMAPK1NPC1SMN1; SMN2GAA
SCHEMBL14714456 0.80 NPC1 (0.56) RAB9ANPC1CTDSP1SMN1; SMN2GAA
SCHEMBL12032244 0.77 CNR2 (0.49) RAB9ACYP1A2NPC1SMN1; SMN2GAA
SCHEMBL14714853 0.77 RAB9A (0.46) RAB9ANPC1CTDSP1SMN1; SMN2GAA
SCHEMBL71818 0.77 RAB9A (0.66) RAB9ANPC1SMN1; SMN2GAAKMT2A
SCHEMBL6416083 0.76 NPC1 (0.60) RAB9ANPC1CTDSP1SMN1; SMN2GAA
SCHEMBL7986974 0.76 PIN1 (0.51) RAB9ACYP1A2MAPK1NPC1SMN1; SMN2
SCHEMBL16097184 0.75 MAPK1 (0.51) RAB9AMAPK1NPC1SMN1; SMN2GAA
SCHEMBL6067713 0.75 MAPT (0.46) RAB9ACYP1A2NPC1SMN1; SMN2KMT2A
SCHEMBL5004806 0.75 NPC1 (0.55) RAB9ANPC1CTDSP1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 RAB9A 2523/4885CYP1A2 3943/4885MAPK1 1038/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 RAB9A 2523/4885CYP1A2 3943/4885MAPK1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.